Radioactive bladder treatment trial seeks to spare patients from surgery
NCT ID NCT07260162
Summary
This early-stage trial is testing the safety of a new radioactive drug called ATO-101 for people with a specific type of bladder cancer that has come back after standard treatments. The drug is delivered directly into the bladder to try to destroy cancer cells while aiming to spare the organ, potentially avoiding major surgery. The main goal is to find the highest dose patients can tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, Loire Atlantique, 44800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.